abs432.txt	importance		oral	anticancer	medications	are	increasingly	important	but	costlytreatment	options	for	patients	with	cancer		by	early	2017		43	states	andwashington		dc		had	passed	laws	to	ensure	patients	with	private	insuranceenrolled	in	fully	insured	health	plans	pay	no	more	for	anticancer	medicationsadministered	by	mouth	than	anticancer	medications	administered	by	infusion	federal	legislation	regarding	this	issue	is	currently	pending		despite	theirrapid	acceptance		the	changes	associated	with	state	adoption	of	oral	chemotherapyparity	laws	have	not	been	described	objective		to	estimate	changes	in	oral	anticancer	medication	use		out-of-pocketspending		and	health	plan	spending	associated	with	oral	chemotherapy	parity	lawadoption	design		setting		and	participants		analysis	of	administrative	health	plan	claimsdata	from	2008-2012	for	3	large	nationwide	insurers	aggregated	by	the	health	carecost	institute		data	analysis	was	first	completed	in	2015	and	updated	in	2017	the	study	population	included	63	780	adults	living	in	1	of	16	states	that	passedparity	laws	during	the	study	period	and	who	received	anticancer	drug	treatmentfor	which	orally	administered	treatment	options	were	available		study	analysisused	a	difference-in-differences	approach	exposures		time	period	before	and	after	adoption	of	state	parity	laws	controlling	for	whether	the	patient	was	enrolled	in	a	plan	subject	to	parity(fully	insured)	or	not	(self-funded		exempt	via	the	employee	retirement	incomesecurity	act)	main	outcomes	and	measures		oral	anticancer	medication	use		out-of-pocketspending		and	total	health	care	spending	results		of	the	63	780	adults	aged	18	through	64	years		51	4%	participated	infully	insured	plans	and	48	6%	in	self-funded	plans	(57	2%	were	women		76	8%	wereaged	45	to	64	years)		the	use	of	oral	anticancer	medication	treatment	as	aproportion	of	all	anticancer	treatment	increased	from	18%	to	22%	(adjusteddifference-in-differences	risk	ratio	[addrr]		1	04		95%	ci		0	96-1	13		p	=		34)comparing	months	before	vs	after	parity		in	plans	subject	to	parity	laws		theproportion	of	prescription	fills	for	orally	administered	therapy	withoutcopayment	increased	from	15	0%	to	53	0%		more	than	double	the	increase(12	3%-18	0%)	in	plans	not	subject	to	parity	(p	<		001)		the	proportion	ofpatients	with	out-of-pocket	spending	of	more	than	$100	per	month	increased	from8	4%	to	11	1%	compared	with	a	slight	decline	from	12	0%	to	11	7%	in	plans	notsubject	to	parity	(p	=		004)		in	plans	subject	to	parity	laws		estimated	monthlyout-of-pocket	spending	decreased	by	$19	44	at	the	25th	percentile		by	$32	13	atthe	50th	percentile		and	by	$10	83	at	the	75th	percentile	but	increased	at	the90th	($37	19)	and	95th	($143	25)	percentiles	after	parity	(all	p	<		001	controlling	for	changes	in	plans	not	subject	to	parity)		parity	laws	did	notincrease	6-month	total	spending	for	users	of	any	anticancer	therapy	or	for	usersof	oral	anticancer	therapy	alone	conclusions	and	relevance		while	oral	chemotherapy	parity	laws	modestly	improvedfinancial	protection	for	many	patients	without	increasing	total	health	carespending		these	laws	alone	may	be	insufficient	to	ensure	that	patients	areprotected	from	high	out-of-pocket	medication	costs	
